Vir Biotechnology, Inc.
NASDAQ:VIRBiotechnology
-$0.25 today
- Market cap
- $1.57B
- Beta
- 1.64
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.00
Volume 2.15M
Average 1.76M
VIR Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Vir Biotechnology, Inc.NASDAQ: VIR
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin remains negative
Q1 FY2026 selling, general & admin was $23.34M, compared with $0 a year earlier. Trailing-twelve-month selling, general & admin was $69.19M.
Context
- Selling, general & admin amounted to 134.3% of revenue in FY2025, up 134.3 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 6 analysts of $344.2M (+273.8%) for the fiscal year ending Dec 2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $23.34M-1.2% QoQ
- Last fiscal yearDec 2025
- $92.07M— YoY
- LTMMar 2026
- $69.19M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | — | +273.8% | — |
| 3-year CAGR | — | +4.5% | — |
| 5-year CAGR | +30.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 92.07M USD
- Year-over-year change
- —
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 92.07M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Selling, General & Admin vs competitors
How VIR compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Selling, general & admin amounts to 105.6% of revenue for VIR, versus a peer median of 32.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $979M USD | -7.7% | -3.5% | 38.8% | |
| LTM Jun 2026 | €788.8M EUR | +45.9% | +8.9% | 29.8% | |
| LTM Jun 2026 | $337.33M USD | +6.9% | +29.8% | 35.9% | |
| LTM Mar 2026 | $127.98M USD | -57.1% | -32.5% | 21.5% | |
| LTM Mar 2026 | €70.46M EUR | -23.0% | +9.1% | 45.1% | |
| LTM Mar 2026 | $69.19M USD | — | — | 105.6% | |
| LTM Mar 2026 | $38.28M USD | -25.4% | -1.1% | 55.3% | |
| LTM Mar 2026 | $30.28M USD | -34.0% | -12.3% | — | |
| LTM Mar 2026 | $19.78M USD | +10.8% | -6.4% | 27.8% | |
| LTM Mar 2026 | $15.94M USD | -39.5% | -3.8% | 8.3% | |
| Peer median (excluding VIR) | — | -23.0% | -3.5% | 32.9% | |
Competitors are the stored peer set for VIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.1B | 1.62B | 86.18M | 74.21M | 68.56M |
| Cost of Revenue | 513.87M | 620.97M | 572.83M | 478.65M | 11.71M |
| Gross Profit | 581.54M | 994.83M | (486.65M) | (404.44M) | 56.85M |
| Gross Margin | 53.1% | 61.6% | -564.7% | -545.0% | 82.9% |
| Research & Development | 448.01M | 474.65M | 579.72M | 506.5M | 432.8M |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 92.07M |
| Operating Expenses | 160.79M | 161.76M | 197.66M | 182.73M | 524.87M |
| Depreciation & Amortization | 5.81M | 6.78M | 19.45M | 14.56M | 11.68M |
| EBITDA | 555.61M | 761.06M | (641.64M) | (508.91M) | (426.09M) |
| EBITDA Margin | 50.7% | 47.1% | -744.5% | -685.8% | -621.5% |
| Operating Income | 420.75M | 833.07M | (684.31M) | (587.17M) | (468.02M) |
| Operating Margin | 38.4% | 51.6% | -794.0% | -791.3% | -682.7% |
| Interest Income | 439K | 28.09M | 86.99M | 71.81M | 40.24M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 129.05M | (78.79M) | 56.11M | 64.06M | 30.25M |
| Income Before Tax | 549.8M | 754.28M | (628.19M) | (523.11M) | (437.77M) |
| Pre-Tax Margin | 50.2% | 46.7% | -728.9% | -704.9% | -638.6% |
| Income Tax Expense | 21.22M | 238.44M | (13.08M) | (1.15M) | 217K |
| Net Income | 528.58M | 515.84M | (615.06M) | (521.96M) | (437.99M) |
| Net Margin | 48.3% | 31.9% | -713.7% | -703.4% | -638.9% |
| EPS (Basic) | 4.07 | 3.89 | (4.59) | (3.83) | (3.16) |
| EPS (Diluted) | 3.96 | 3.83 | (4.59) | (3.83) | (3.16) |
| Weighted Avg Shares | 129.88M | 132.61M | 134.13M | 136.25M | 138.52M |
| Weighted Avg Shares (Diluted) | 133.44M | 134.81M | 134.13M | 136.25M | 138.52M |
Vir Biotechnology, Inc.
NASDAQ:VIR
Intrinsic Alpha fair value
Locked
Current Price
$9.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.